| Group | Autoantibody positivity population (panel of 7) | ||
| All samples | Subset 0–1 | Subset 0–6 | |
| 0–36 months | 0–1 month Pre-Tx | 0–6 months Pre-Tx | |
| SCLC | |||
| Number +ve | 15/22 | 5/8 | 9/13 |
| % +ve (95% CI) | 68 (45 to 86) | 63 (24 to 91) | 69 (39 to 91) |
| NSCLC | |||
| Squamous | |||
| Number +ve | 23/25 | 5/5 | 11/12 |
| % +ve (95% CI) | 92 (74 to 99) | 100 (48 to 100) | 92 (62 to 100) |
| Adeno | |||
| Number +ve | 27/35 | 5/7 | 13/16 |
| % +ve (95% CI) | 77 (60 to 90) | 71 (29 to 96) | 81 (54 to 96) |
| NOS | |||
| Number +ve | 14/22 | 0/2 | 2/6 |
| % +ve (95% CI) | 64 (41 to 83) | 0 (0 to 84) | 33 (4 to 78) |
| All LC | |||
| Number +ve | 79/104 | 15/22 | 35/47 |
| % +ve (95% CI) | 76 (67 to 84) | 68 (45 to 86) | 74 (60 to 86) |
| p Value from χ2 test* | 0.107 | 0.211 | 0.285 |
Number and percentage positivity (% +ve) with 95% confidence interval (95% CI) in each patient group using panel 1/7. Analysis repeated on two subset sample populations taking only pretreatment (pre-Tx) samples up to 1 month and 6 months from diagnosis.
*χ2 Test across cancer subgroups noting that NOS was pooled with adeno in the subset analyses owing to small numbers.
All LC, all lung cancer samples tested; SCLC, small cell lung cancer; NSCLC, non-small cell lung cancer; Adeno, adenocarcinoma; Squamous, squamous cell carcinoma; NOS, not otherwise specified.